Measurement and treatment of radiographic progression in ankylosing spondylitis: Lessons learned from observational studies and clinical trials

Grant H. Louie, Michael M. Ward

Research output: Contribution to journalArticle

Abstract

PURPOSE OF REVIEW: One of the major goals of treatment of ankylosing spondylitis is to prevent or slow the development of spinal new bone formation. Recent observational studies are compared with the results from clinical trials for the effects of tumor necrosis factor-alpha inhibitors (TNFi) and NSAIDs on radiographic measures of spinal damage. RECENT FINDINGS: Data from clinical trials indicate that treatment up to 2 years with TNFi was not associated with a difference in rates of progression of spinal damage, compared with historical controls. These studies were based on open-label extensions, and analyzed as cohort studies. Recent observational studies have suggested that TNFi may reduce radiographic progression. The different conclusions may be related to the longer treatment and observation period of these observational studies, which may have permitted detection of changes in this slowly evolving process. There is emerging evidence from a clinical trial and retrospective studies that continuous NSAID use may slow radiographic progression. SUMMARY: Lack of evidence that TNFi slows radiographic progression in ankylosing spondylitis in data from clinical trials may be because of the design of these studies, and possibly not a true null treatment effect.

Original languageEnglish (US)
Pages (from-to)145-150
Number of pages6
JournalCurrent Opinion in Rheumatology
Volume26
Issue number2
DOIs
StatePublished - Mar 2014

Fingerprint

Ankylosing Spondylitis
Observational Studies
Tumor Necrosis Factor-alpha
Clinical Trials
Non-Steroidal Anti-Inflammatory Agents
Osteogenesis
Cohort Studies
Retrospective Studies
Observation

Keywords

  • ankylosing spondylitis
  • measurement
  • radiographic progression
  • treatment

ASJC Scopus subject areas

  • Rheumatology

Cite this

Measurement and treatment of radiographic progression in ankylosing spondylitis : Lessons learned from observational studies and clinical trials. / Louie, Grant H.; Ward, Michael M.

In: Current Opinion in Rheumatology, Vol. 26, No. 2, 03.2014, p. 145-150.

Research output: Contribution to journalArticle

@article{a81c311a4e1446649f124b3c611b28cf,
title = "Measurement and treatment of radiographic progression in ankylosing spondylitis: Lessons learned from observational studies and clinical trials",
abstract = "PURPOSE OF REVIEW: One of the major goals of treatment of ankylosing spondylitis is to prevent or slow the development of spinal new bone formation. Recent observational studies are compared with the results from clinical trials for the effects of tumor necrosis factor-alpha inhibitors (TNFi) and NSAIDs on radiographic measures of spinal damage. RECENT FINDINGS: Data from clinical trials indicate that treatment up to 2 years with TNFi was not associated with a difference in rates of progression of spinal damage, compared with historical controls. These studies were based on open-label extensions, and analyzed as cohort studies. Recent observational studies have suggested that TNFi may reduce radiographic progression. The different conclusions may be related to the longer treatment and observation period of these observational studies, which may have permitted detection of changes in this slowly evolving process. There is emerging evidence from a clinical trial and retrospective studies that continuous NSAID use may slow radiographic progression. SUMMARY: Lack of evidence that TNFi slows radiographic progression in ankylosing spondylitis in data from clinical trials may be because of the design of these studies, and possibly not a true null treatment effect.",
keywords = "ankylosing spondylitis, measurement, radiographic progression, treatment",
author = "Louie, {Grant H.} and Ward, {Michael M.}",
year = "2014",
month = "3",
doi = "10.1097/BOR.0000000000000025",
language = "English (US)",
volume = "26",
pages = "145--150",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Measurement and treatment of radiographic progression in ankylosing spondylitis

T2 - Lessons learned from observational studies and clinical trials

AU - Louie, Grant H.

AU - Ward, Michael M.

PY - 2014/3

Y1 - 2014/3

N2 - PURPOSE OF REVIEW: One of the major goals of treatment of ankylosing spondylitis is to prevent or slow the development of spinal new bone formation. Recent observational studies are compared with the results from clinical trials for the effects of tumor necrosis factor-alpha inhibitors (TNFi) and NSAIDs on radiographic measures of spinal damage. RECENT FINDINGS: Data from clinical trials indicate that treatment up to 2 years with TNFi was not associated with a difference in rates of progression of spinal damage, compared with historical controls. These studies were based on open-label extensions, and analyzed as cohort studies. Recent observational studies have suggested that TNFi may reduce radiographic progression. The different conclusions may be related to the longer treatment and observation period of these observational studies, which may have permitted detection of changes in this slowly evolving process. There is emerging evidence from a clinical trial and retrospective studies that continuous NSAID use may slow radiographic progression. SUMMARY: Lack of evidence that TNFi slows radiographic progression in ankylosing spondylitis in data from clinical trials may be because of the design of these studies, and possibly not a true null treatment effect.

AB - PURPOSE OF REVIEW: One of the major goals of treatment of ankylosing spondylitis is to prevent or slow the development of spinal new bone formation. Recent observational studies are compared with the results from clinical trials for the effects of tumor necrosis factor-alpha inhibitors (TNFi) and NSAIDs on radiographic measures of spinal damage. RECENT FINDINGS: Data from clinical trials indicate that treatment up to 2 years with TNFi was not associated with a difference in rates of progression of spinal damage, compared with historical controls. These studies were based on open-label extensions, and analyzed as cohort studies. Recent observational studies have suggested that TNFi may reduce radiographic progression. The different conclusions may be related to the longer treatment and observation period of these observational studies, which may have permitted detection of changes in this slowly evolving process. There is emerging evidence from a clinical trial and retrospective studies that continuous NSAID use may slow radiographic progression. SUMMARY: Lack of evidence that TNFi slows radiographic progression in ankylosing spondylitis in data from clinical trials may be because of the design of these studies, and possibly not a true null treatment effect.

KW - ankylosing spondylitis

KW - measurement

KW - radiographic progression

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=84894065143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894065143&partnerID=8YFLogxK

U2 - 10.1097/BOR.0000000000000025

DO - 10.1097/BOR.0000000000000025

M3 - Article

C2 - 24389865

AN - SCOPUS:84894065143

VL - 26

SP - 145

EP - 150

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 2

ER -